Steven J O'Day - JoVE Visualize

Showing results (41-50 of 61) with videos related to

Pageof 7

Sort By:

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010

Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanomaKazuo Koyanagi, Steven J O'Day, Peter Boasberg, et al.

Clinical Chemistry|November 2, 2019

Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial ImmunotherapySelena Y Lin, Shu-Ching Chang, Stella Lam, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013

Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanomaSteven J O'Day, Alexander M M Eggermont, Vanna Chiarion-Sileni, et al.

Lancet (London, England)|May 22, 2012

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialGerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.

Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 14, 2017

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access ProgramTara C Gangadhar, Wen-Jen Hwu, Michael A Postow, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2014

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)Gerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.

JAMA Oncology|July 17, 2020

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical TrialsIgor Puzanov, Antoni Ribas, Caroline Robert, et al.

Journal of Neuro-Oncology|July 20, 2002

An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitisKurt A Jaeckle, Tracy Batchelor, Steven J O'Day, et al.

Journal for Immunotherapy of Cancer|December 23, 2025

Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancerRebecca Porter, Bruno Bockorny, Bradley R Corr, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2013

Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical OncologyJyoti D Patel, Lada Krilov, Sylvia Adams, et al.

Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:

Pageof 7

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010

Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanomaKazuo Koyanagi, Steven J O'Day, Peter Boasberg, et al.

Clinical Chemistry|November 2, 2019

Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial ImmunotherapySelena Y Lin, Shu-Ching Chang, Stella Lam, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013

Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanomaSteven J O'Day, Alexander M M Eggermont, Vanna Chiarion-Sileni, et al.

Lancet (London, England)|May 22, 2012

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialGerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.

Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 14, 2017

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access ProgramTara C Gangadhar, Wen-Jen Hwu, Michael A Postow, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2014

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)Gerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.

JAMA Oncology|July 17, 2020

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical TrialsIgor Puzanov, Antoni Ribas, Caroline Robert, et al.

Journal of Neuro-Oncology|July 20, 2002

An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitisKurt A Jaeckle, Tracy Batchelor, Steven J O'Day, et al.

Journal for Immunotherapy of Cancer|December 23, 2025

Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancerRebecca Porter, Bruno Bockorny, Bradley R Corr, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2013

Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical OncologyJyoti D Patel, Lada Krilov, Sylvia Adams, et al.

Pageof 7